Sofituzumab Vedotin
- CAS No.
- 1418200-58-4
- Chemical Name:
- Sofituzumab Vedotin
- Synonyms
- Sofituzumab Vedotin;Sofituzumab vedotin (ADC);Research Grade Sofituzumab;Sofituzumab vedotin (anti-MUC16)
- CBNumber:
- CB78080896
- Molecular Formula:
- Molecular Weight:
- 0
- MDL Number:
- MOL File:
- Mol file
- MSDS File:
- SDS
| form | Liquid |
|---|---|
| color | Colorless to light yellow |
| FDA UNII | 2X3CKG601L |
Sofituzumab Vedotin price
| Manufacturer | Product number | Product description | CAS number | Packaging | Price | Updated | Buy |
|---|---|---|---|---|---|---|---|
| ChemScene | CS-0628998 | Sofituzumab vedotin 98.97% | 1418200-58-4 | 1mg | $1029 | 2026-06-04 | Buy |
| ChemScene | CS-0628998 | Sofituzumab vedotin 98.97% | 1418200-58-4 | 5mg | $2578 | 2026-06-04 | Buy |
| ChemScene | CS-0628998 | Sofituzumab vedotin 98.97% | 1418200-58-4 | 10mg | $4117 | 2026-06-04 | Buy |
| aablocks | AA02E6G3 | Sofituzumab vedotin ≥90%(SDS-PAGE&SEC-HPLC) | 1418200-58-4 | 1mg | $1510 | 2026-06-03 | Buy |
| aablocks | AA02E6G3 | Sofituzumab vedotin ≥90%(SDS-PAGE&SEC-HPLC) | 1418200-58-4 | 5mg | $3776 | 2026-06-03 | Buy |
Sofituzumab Vedotin Chemical Properties, Uses, Production
Uses
Sofituzumab vedotin (DMUC5754A) is a MMAE-containing anti-MUC16 antibody-drug conjugate (ADC) with a protease-cleavable linker. Sofituzumab vedotin can be used for the research of cancer[1].
in vivo
Sofituzumab vedotin (3A5-VC-MMAE; 2 and 2.8 mg/kg; IV; once weekly for 3 or 4 total doses) shows potent anti-tumor activity in MUC16-expressing human OVCAR-3 mouse xenograft models[3].
| Animal Model: | Female CB17 ICR severe combined immunodeficient mice, OVCAR-3/luc mouse xenografts[3] |
| Dosage: | 2.8 mg/kg |
| Administration: | IV, once weekly for 4 total doses |
| Result: | Improved survival. |
| Animal Model: | Female CB17 ICR severe combined immunodeficient mice, OVCAR-3 tumors grown in the mammary fat pads[3] |
| Dosage: | 2 mg/kg |
| Administration: | IV, once weekly for 3 total doses |
| Result: | Significantly decreased the tumor volume. |
References
[1] Manzano A, et al. Antibody-Drug Conjugates: A Promising Novel Therapy for the Treatment of Ovarian Cancer. Cancers (Basel). 2020 Aug 9;12(8):2223. DOI:10.3390/cancers12082223
[2] Liu JF, et al. Phase I study of safety and pharmacokinetics of the anti-MUC16 antibody-drug conjugate DMUC5754A in patients with platinum-resistant ovarian cancer or unresectable pancreatic cancer. Ann Oncol. 2016 Nov;27(11):2124-2130. DOI:10.1093/annonc/mdw401
[3] Chen Y, et al. Armed antibodies targeting the mucin repeats of the ovarian cancer antigen, MUC16, are highly efficacious in animal tumor models. Cancer Res. 2007 May 15;67(10):4924-32. DOI:10.1158/0008-5472.CAN-06-4512
Sofituzumab Vedotin Preparation Products And Raw materials
Raw materials
Preparation Products
Sofituzumab Vedotin Suppliers
| Supplier | Tel | Country | ProdList | Advantage | |
|---|---|---|---|---|---|
| Shanghai YuanYe Biotechnology Co., Ltd. | 15026964105 | 2881489226@qq.com | China | 89667 | 60 |
| ShangHai Biochempartner Co.,Ltd | 177-54423994 17754423994 | 2853530910@QQ.com | China | 8000 | 62 |
| Wuhan Chemstan Biotechnology Co., Ltd. | 027-65317797 15926423062 | 422450190@qq.com | China | 10305 | 58 |
| Beijing Jin Ming Biotechnology Co., Ltd. | 010-60605840 | psaitong@jm-bio.com | China | 27626 | 58 |
| Wuhan Jingkangen Biomedical Technology Co., Ltd | 13720134139 086-15871494362 13720134139 | orders@jknbiochem.com | China | 7283 | 58 |
| Shanghai Yifei Biotechnology Co. , Ltd. | 021-65675885 18964387627 | customer_service@efebio.com | China | 11963 | 58 |
| Wuhan Peptide Core Biotechnology Co., Ltd | 027-65317797 13667154760 | 1096814016@qq.com | China | 10711 | 58 |
| Changsha Fuzhen Biotechnology Co.，LTD | 15111215862 18229892877 | 3062105966@qq.com | China | 5568 | 58 |
| bioleaper | 4000880777 17585207275 | guojing@bioleaper.com | China | 5616 | 58 |
| Olix ( Hubei) Pharmaceutical Technology Co., Ltd | 17316404525 17316404525 | 209533805@qq.com | China | 9769 | 58 |
